Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 17, 2021 07:00 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
April 29, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15...
Angion_2IN-02.jpg
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
March 30, 2021 16:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia
March 25, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Angion_2IN-02.jpg
Angion Announces Partial Waiver of Certain Lock-up Restrictions
March 19, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion to Participate in Upcoming March Investment Conferences
February 24, 2021 00:05 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion_2IN-02.jpg
Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 09, 2021 16:10 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Angion_2IN-02.jpg
Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement
February 05, 2021 08:30 ET | Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...